Abeona Therapeutics' (ABEO) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• Abeona Therapeutics received a "buy" rating from HC Wainwright, with a target price of $20.00, indicating a potential upside of 180.50% from its current price.
• The company's recent earnings report showed a significant outperformance, with earnings per share of $1.71 compared to the consensus estimate of (0.39).
• Insider selling included notable transactions by Director Christine Berni Silverstein and CFO Joseph Walter Vazzano, indicating a decrease in their stock holdings.

HC Wainwright reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $20.00 target price on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Abeona Therapeutics' Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $1.49 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.42 EPS.

Several other equities analysts have also recently issued reports on the company. Stifel Nicolaus reduced their price objective on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Oppenheimer increased their target price on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, August 15th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Finally, Wall Street Zen lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Abeona Therapeutics currently has an average rating of "Buy" and an average target price of $19.50.

Abeona Therapeutics Stock Performance

ABEO traded up $0.12 during trading hours on Monday, hitting $7.23. 850,820 shares of the stock were exchanged, compared to its average volume of 710,270. The stock has a 50-day simple moving average of $6.30 and a 200-day simple moving average of $5.79. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.54. The stock has a market cap of $370.75 million, a price-to-earnings ratio of 10.33 and a beta of 1.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.73 and a quick ratio of 4.90.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $21.71 million. Analysts anticipate that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Insider Activity at Abeona Therapeutics

In other news, CFO Joseph Walter Vazzano sold 25,411 shares of the firm's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $148,908.46. Following the transaction, the chief financial officer directly owned 479,168 shares of the company's stock, valued at approximately $2,807,924.48. This trade represents a 5.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Alvino sold 13,093 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $76,724.98. Following the transaction, the director directly owned 77,252 shares in the company, valued at $452,696.72. This trade represents a 14.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 231,626 shares of company stock valued at $1,430,587. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ABEO. Jane Street Group LLC grew its holdings in Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock worth $732,000 after acquiring an additional 118,262 shares during the period. Wellington Management Group LLP acquired a new position in Abeona Therapeutics during the fourth quarter worth about $520,000. Squarepoint Ops LLC acquired a new position in Abeona Therapeutics during the fourth quarter worth about $67,000. Northern Trust Corp grew its holdings in Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock worth $1,030,000 after acquiring an additional 11,478 shares during the period. Finally, Bank of America Corp DE grew its holdings in Abeona Therapeutics by 16.7% during the fourth quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company's stock worth $1,473,000 after acquiring an additional 37,774 shares during the period. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.